Tirzepatide

What is Tirzepatide?

Tirzepatide is a synthetic 39-amino-acid dual agonist peptide that binds both the GIP receptor and the GLP-1 receptor — a "twincretin" pharmacology approach that has been the subject of significant metabolic research.

Research mechanism

Published research has examined the following mechanisms:

• GLP-1R activation — cAMP/PKA signaling in receptor-expressing cell lines.
• GIPR activation — additional signaling through GIP receptor pathways.
• Biased agonism — preference for G-protein signaling over β-arrestin recruitment.
• Half-life extension — C20 fatty acid enables strong albumin binding (~5 day research half-life).

Note: All mechanism data is from published research. Not FDA-approved for human use.

Physical properties & handling

Reconstitute 15 mg with 1.5 mL bacteriostatic water (10 mg/mL). Swirl gently, never vortex. Refrigerate 2–8°C; use within 28 days.

Quality specifications (Broceutical Tirzepatide)

• Purity: 99.5% typical (HPLC verified)
• Identity: LC-MS/MS confirmed
• Endotoxin: <1 EU/mg (LAL)
• Form: Lyophilized powder

Published research references

• Coskun T, et al. "LY3298176, a novel dual GIP and GLP-1 receptor agonist." Mol Metab. 2018;18:3-14. PubMed PMID: 30473097
• Willard FS, et al. "Tirzepatide is an imbalanced and biased dual GIP and GLP-1 receptor agonist." JCI Insight. 2020;5(17):e140532. PubMed PMID: 32730231
• PubMed literature search https://pubmed.ncbi.nlm.nih.gov/?term=tirzepatide

Broceutical does not endorse or make claims from the above research.